Novel Device for the Evaluation of Hemostasis is used to determine the presence of residual heparin in the sample. Channel 3 is optimized for the measurement of Clot Stiffness, which combines information about platelets and fibrinogen function. Finally, channel 4 is optimized to measure the Fibrinogen Contribution to clot stiffness. Both channels 3 and 4 use hexadimethrine bromide to neutralize residual heparin. The difference between Clot Stiffness and Fibrinogen Contribution represents the Platelet Contribution to clot stiffness. 18, 19 The Quantra test results are summarized in Table 2 . Figure 2 shows representative shear modulus versus time curves obtained with the Surgical Cartridge. The top panel shows curves obtained from a normal subject but in the presence of 6 IU/ml of unfractionated heparin in the sample. The bottom panel shows curves obtained from a sample with reduced fibrinogen levels. The device is designed to generate complete test results within 15 minutes of test initiation.
SEER Sonorheometry
SEER Sonorheometry is a patented technology that uses high-frequency ultrasound pulses to quantify the shear modulus (ie, stiffness) of a blood sample during the process of coagulation. 15 The shear modulus is a parameter that describes the elastic properties of a solid material. 20 For example, the shear modulus of bone tissue is approximately 3.3 GPa, whereas natural rubber is typically approximately 600 Pa. The technology is shown schematically in Figure 3 .
A focused ultrasound pulse is transmitted into the blood sample to generate a shear wave, causing the sample to resonate once the clot begins to form (left panel). As the clot vibrates during resonance, a series of "tracking" ultrasound pulses are transmitted and the returning echoes are analyzed to estimate the sample's motion (middle panel). The shape of the estimated displacement curve is directly related to the shear modulus of the sample. The time-displacement curve can be compared to theoretic models to determine the actual shear modulus for that specific point in time. Repeated acquisitions over time form a signature curve that shows the dynamic changes in shear modulus of the sample during coagulation (right panel). From this curve, the start of clot formation, or clot time, and the stiffness of the clot can be directly estimated. The combination of these 2 parameters provides information about the functional role of the coagulation factors, fibrinogen, and platelets in the sample.
In these experiments, the shear modulus values were estimated by interrogating the blood sample every 4 seconds. Clot time, expressed in minutes, is estimated by determining the time at which the rate of change in stiffness exceeds a predefined threshold value. Clot stiffness is estimated by identifying the shear modulus value at a specific time point after clot time. This parameter is expressed in units of hectopascal, or hPa (ie, 1 hPa = 100 Pa).
Validation and Comparative Studies
Experiments described here were performed using a plasma-based control material and whole blood samples (obtained in 3.2% sodium citrate) from healthy volunteers. Comparative studies were performed against the TEG 5000 and the Clauss fibrinogen assay implemented in the Stago STart4 Hemostasis analyzer (Stago, Asnières-sur-Seine, France). Detailed descriptions of blood collection, blood processing procedures, and comparative studies are described in the Supplemental Digital Content (http://links.lww. com/AA/B440).
RESULTS

Technology Reproducibility
Assay reproducibility was assessed with both whole blood samples and the plasma-based control materials over a period of 5 days. In the case of whole blood samples, a different volunteer was used for each day. A modified set of reagents was used in the cartridge as heparinase I and 
Assessment of Coagulation Function
The effects of the coagulation factors on Clot Time were investigated by titrating varying amounts of low-molecular-weight heparin (LMWH) with samples from healthy volunteers to achieve final concentrations of 0, 1, 2, and 4 IU/mL. All the cartridge channels were loaded with channel 1 reagents (see Table 1 ), hence activating the sample with kaolin. The results presented in the dose-response curve in Figure 4 demonstrate that increasing amounts of LMWH delayed the formation of the fibrin as indicated by a prolonged Clot Time. 21 Additional experiments were performed using samples that were untreated, spiked with a low dose of unfractionated heparin, or where the endogenous plasma was replaced with factor VIII-, X-, or XII-deficient plasmas. The same experimental conditions (same sample and reagents) were assessed in parallel by using the TEG, resulting in multiple paired measurements. The results are summarized in Figure 5 , which demonstrates that Quantra Clot Time and TEG R values are well correlated over the range of conditions analyzed (r value of 0.95; n = 34; 99% CI, [0.88-0.98]).
Assessment of Platelet Contribution to Clot Stiffness
The effects of platelet function on SEER Sonorheometry measurements are shown in Figure 6 (top panel), where samples from healthy volunteers were treated with increasing amounts of abciximab, a potent GPIIb/IIIa receptor antagonist. 22, 23 All the cartridge channels were loaded with channel 3 reagents (see Table 1 ), hence activating the sample with thromboplastin. In this figure, Clot Stiffness decreases monotonically as a function of abciximab concentration converging toward a plateau at approximately 6 μg/mL. Above this concentration, the measured stiffness is indicative of the fibrin network alone with little to no contribution from platelets. This figure also shows that Clot Stiffness decreased by approximately 7-fold over the range reported in this figure, emphasizing the role of platelets in determining the final mechanical stiffness of the mature clot.
Experiments were performed in parallel with the TEG using the same blood samples dosed with abciximab. The results are summarized in Figure 6 Figure 7 shows the effects of fibrinogen content on SEER Sonorheometry measurements of Fibrinogen Contribution. All the cartridge channels were loaded with channel 4 reagents (see Table 1 ), hence activating the sample with the combination of thromboplastin and a saturating dose of abciximab to remove the platelet's ability to modulate clot stiffness. For each of the 5 subjects enrolled, the target fibrinogen concentration was in the range of 75 to 286 mg/dL, spanning the pathologically low to normal range. The data shown in the top panel of Figure 7 indicate that, for each subject, fibrinogen contribution varied linearly over the range of 75 to 286 mg/dL. The bottom panel of Figure 7 shows the pooled Quantra data compared with plasma fibrinogen measured with the STart4. The correlation of 0.94 (n = 29; 99% CI, [0.87-0.98]) observed between the 2 technologies is high, demonstrating the ability of SEER Sonorheometry to measure low fibrinogen concentrations.
Assessment of Fibrinogen Contribution to Clot Stiffness
DISCUSSION
In this work, we introduced and characterized the Quantra Hemostasis Analyzer, a novel platform for the viscoelastic assessment of whole blood coagulation, and evaluated its reproducibility and ability to assess the function of key hemostatic components. The Quantra has been designed and optimized for ease of use, complete system automation, and rapid turnaround time to enable utilization at the point of care or near patient. The SEER Sonorheometry technology utilized in the Quantra is a patented method that does not require moving mechanical components to be in direct contact with the blood sample being measured. SEER Sonorheometry measures changes in shear modulus of the sample during coagulation to estimate the onset of clot formation and the clot stiffness generated by the combination of fibrin network and activated platelets.
The data presented suggest that SEER Sonorheometry can perform precise measurements for both the determination of clot time and clot stiffness in whole blood with CVs in the range of 2.4% to 8.8%. Figures 4 and 5 show Clot Time measurements over varying anticoagulant concentrations and coagulation factor deficiencies. The data presented in Figures 6 and 7 show the effects of varying levels of functional platelets and fibrinogen content to clot stiffness. These experiments revealed that the shear modulus measured in whole blood is approximately 7 times greater than the contribution provided by fibrinogen alone. We hypothesize that this wide dynamic range stems from the fact that SEER Sonorheometry is noncontact and applies low shear strains, allowing for the measurement of very soft clots that are often associated with clinical bleeding. The data also demonstrate that, under the conditions tested here, the Quantra exhibited good correlation with other well-established devices such as the TEG and the Clauss assay performed on the STart4 (Figures 5-7) .
In conclusion, these studies indicate that SEER Sonorheometry combined with the Quantra Surgical Cartridge can provide a rapid and precise measure of Clot Time, Clot Stiffness, and Platelet and Fibrinogen Contributions to clot stiffness, and the presence of heparin anticoagulation. Each of these test results could be used, together with other clinical information, to provide comprehensive information and guide treatments intended to restore balanced hemostasis. Additional studies are warranted to demonstrate the clinical utility of the Quantra and the Surgical Cartridge. We hypothesize that the comprehensive information that the device is capable of providing could have numerous potential clinical applications besides the surgical settings, such as in the case of advanced liver disease, cancer, and trauma.
